Preclinical Data
Mozart Therapeutics Presents Compelling New Preclinical Data on MTX-201 at the 2025 Crohn's and Colitis Congress
Mozart Therapeutics
PR-02-25-NI-01Feb 07, 2025
Annual Congress
Hemab Shares Phase 2 HMB-001 Data for Glanzmann Thrombasthenia & HMB-002 Preclinical Data for Von Willebrand at EAHAD 2025
Hemab Therapeutics
PR-01-25-NI-35Feb 07, 2025
Preclinical Data
Poseida Therapeutics to Present New Preclinical Data Supporting Non-Viral Gene for the Treatment of Hereditary Angioedema
Poseida Therapeutics
PR-10-24-NI-63Oct 25, 2024
Clinical Data
Skyhawk Therapeutics Presents Compelling Preclinical Data at the Molecular Targets and Cancer Therapeutics Symposium
Skyhawk
PR-10-24-NI-62Oct 25, 2024
Preclinical Data
Transforming Drug Development with Frictionless Access to Real-Time Preclinical Data
Mark Mintz; Kristen M. Eisenhauer
Charles River Laboratories
PAO-05-23-CL-03May 05, 2023
Therapeutic Candidate
CytoDyn Takes Steps towards a Brighter Future
Cyrus Arman, Ph.D.
CytoDyn
PAO-02-23-CL-04Feb 06, 2023
Antibodies
Twist Bioscience Announces Positive Preclinical Data for SARS-CoV-2 Antibodies
Twist Bioscience
PR-M11-20-022-1179Nov 24, 2020
CAR-T Immunotherapy
Cabaletta Bio Announces Presentation of Preclinical Data Showing Specific CAAR T Activity against Anti-MuSK Expressing B Cells
Cabaletta Bio
PR-M10-19-NI-024Oct 15, 2019
Diabetes
Preclinical Studies Bode Well for Diabetes Drug from Semma Therapeutics
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-M07-19-NI-009Jul 10, 2019
Cell and Gene Therapy
Sangamo Therapeutics Presents New Preclinical Data Demonstrating Significant Reduction In Tau Expression With Gene Regulation Technology
Sangamo Therapeutics
PR-M04-19-NI-012Apr 03, 2019
Preclinical Data
Alligator Bioscience: New Preclinical Data Demonstrate Strong Anti-tumor Effects for the 4-1BB Antibody ATOR-1017
Nice Insight
PR-M03-19-NI-053Mar 20, 2019
Preclinical Data
Artemis Therapeutics Announces Two Recent Publications Highlighting Artemisone's Activity Against Human Cytomegalovirus And Malaria
Artemis Therapeutics
PR-M06-18-NI-063Jun 20, 2018
Preclinical Data
Recently Presented Preclinical Data Show Potential for ADXS-NEO as Anti-Cancer Immunotherapy Agent
Advaxis, Inc.
PR-M05-18-NI-056May 15, 2018